Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 June 2019

Cathay Industrial Biotech
CHF
193
million
CHF
64
million
Y-mAbs Therapeutics
Pacira Pharmaceuticals
CHF
40
million
CHF
37
million
Neurelis
CHF
34
million
Turning Point Therapeutics
Harmony Biosciences
CHF
32
million
Vectura Group
CHF
32
million